London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The moment that Dr Peter Sargent joined PYC last year, first as CSO and now as CEO, conveyed a game changing moment for this little company. He's held senior management roles at global consultancy business Syneos Health Inc (NASDAQ: SYNH), & was Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK. He obviously liked what he saw at PYC and joined the company for a reason. 2024 looks a far more promising time to be invested in PYC as a result.
You would imagine from his track record that he's pretty well connected and has the ability to attract and negotiate much bigger contract awards than the previous regime. It will be interesting to hear how things are progressing at 12 Noon today.....
Good luck, Brighty
12.00 noon today
Good news, fake spread, can still buy at 1.375
Yes King
Also an outside we could maybe beat the expectations (Pyc said said would be met last week)
The Company's pipeline of potential new business now stands at over £1.5m (not risk weighted and excluding Biostatistics), counting only opportunities where a specific project has been discussed with a client. The Company is working hard to both convert opportunities that have progressed to proposal stage and also to refill the funnel with earlier stage opportunitie
You mean the 1.5 M revenues as per the interims results
Kudos to some of the posters here said that a contract would land before the IM meeting today.
DNA damge, so looks like Merck have given us another contract.
Merck it sounds like
Looking forward to beating those £1mln revenues
The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in the field of DNA damage/ repair field and will help inform clinical dose and scheduling decisions. The value of the project is £178k and it is anticipated that it will be completed over the course of the next six months.
Dr Peter Sargent, CEO, commented: "We are very pleased that we've been awarded this substantial project and we very much look forward to working with the client team on this exciting project".
Https://www.londonstockexchange.com/news-article/PYC/contract-award/16381053?showDisclaimer=true
I think what Laura maybe alluding to, albeit very loosely, is that sometimes when VAL has a spike, SP or volume wise, it could mean 201 is near?
Laura.
Wrong board. This is PYC not VAL.!!!
VAL
It would be normal to tweet from the conference , they do it at every conference?
I guess they are damned if they do and damned if they dont.
They also tweeted this yesterday https://twitter.com/Physiomics/status/1767847005152309351 about FDA guidance on ADC's trouble is they did not "tag" FDA using their FDA handle, maybe because there are so many?
Looks like not much interest if they have to put a tweet out at 11:45 informing their presence there.
https://x.com/physiomics/status/1767879752117797059?s=61&t=0G9XeE3tHfuoBf1VEsPycQ
I do not hold any hope of any director buys. That question has been asked and answered before, with their reply ( pre Peter ) being a big fat no.
Personally I'm glad that traders are deterred who buy and sell for 5% ,however would be good to have a more realistic spread as you say
Of you look at results across AIM this last month PYC are one of the few that are growing revenues and reducing losses !
Hopefully hear more from the conference and see some director buys
Not that there is any momentum here at the moment, throw in a 20% spread and that kills any potential trader interest.
The pricing is on the Web link...
If one pays x but gets Y back in contracts after meeting clients then it's clearly worth it
The only issue i would have is that these conference presentations / sponsorship / attendance costs money, hopefully they can speculate how much money they can get back from these conferences etc
Merck Sept 2023 contract said more before end of financial year while Bicycle have regularly been expanding their spending with PYC
This is what oeter said in interins
A significant number of new client contracts are now originating from both scientific conferences (such as EORTC-NCI-AACR & AACR Annual Meeting) as well as more business focused meetings (such as BioEurope) and as such the Company intends to significantly increase its presence at such meetings over the course of this calendar year.
Merck KgaA are also there.
May get some new business from both Bicycle and Merck as we have long standing working relationship with them?
Thanks Debull
Some large names like AstraZeneca there too..also Bicycle are doing
A main presentation on one of the days about their programme of assets
Several complementary options are being pursued simultaneously to build out this new capability and a further update will be provided to the market towards the end of the current financial year. We anticipate that, if successful, this new service line could make a material contribution
I am going to ask about this for the pre submitted questions
Is that 20 lots of 33 shares bought ? 666 in total